{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:33:54Z","timestamp":1790393634140,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"vor","delay-in-days":1436,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1002\/rth2.12160","type":"journal-article","created":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T07:20:20Z","timestamp":1542352820000},"page":"26-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"title":["Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicine"],"prefix":"10.1016","volume":"3","author":[{"given":"Paul","family":"Coppo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Cuker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James N.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1002\/rth2.12160_bb0010","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12160_bb0015","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","article-title":"von Willebrand factor\u2010cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic\u2010uremic syndrome","volume":"339","author":"Furlan","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12160_bb0020","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von Willebrand factor\u2010cleaving protease in acute thrombotic thrombocytopenic purpura","volume":"339","author":"Tsai","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12160_bb0025","doi-asserted-by":"crossref","first-page":"17020","DOI":"10.1038\/nrdp.2017.20","article-title":"Thrombotic thrombocytopenic purpura","volume":"3","author":"Kremer Hovinga","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1002\/rth2.12160_bb0030","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"key":"10.1002\/rth2.12160_bb0035","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1016\/S2352-3026(16)30018-7","article-title":"Epidemiology and pathophysiology of adulthood\u2010onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross\u2010sectional analysis of the French national registry for thrombotic microangiopathy","volume":"3","author":"Mariotte","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1002\/rth2.12160_bb0040","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/bloodadvances.2017005124","article-title":"Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long\u2010term outcomes from 1995 through 2015","volume":"1","author":"Page","year":"2017","journal-title":"Blood Adv"},{"key":"10.1002\/rth2.12160_bb0045","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1538-7836.2009.03285.x","article-title":"Cardiac involvement in acute thrombotic thrombocytopenic purpura: association with troponin T and IgG antibodies to ADAMTS 13","volume":"7","author":"Hughes","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12160_bb0050","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/jth.12790","article-title":"Cardiac troponin\u2010I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center","volume":"13","author":"Benhamou","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12160_bb0055","doi-asserted-by":"crossref","first-page":"e0177894","DOI":"10.1371\/journal.pone.0177894","article-title":"Predictive features of chronic kidney disease in atypical haemolytic uremic syndrome","volume":"12","author":"Jamme","year":"2017","journal-title":"PLoS One"},{"key":"10.1002\/rth2.12160_bb0060","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ajh.24665","article-title":"Thrombotic thrombocytopenic purpura misdiagnosed as autoimmune cytopenia: causes of diagnostic errors and consequence on outcome. Experience of the French thrombotic microangiopathies reference centre","volume":"92","author":"Grall","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1002\/rth2.12160_bb0065","doi-asserted-by":"crossref","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"key":"10.1002\/rth2.12160_bb0070","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol"},{"issue":"Suppl 1","key":"10.1002\/rth2.12160_bb0075","first-page":"LBA","article-title":"Results of the randomized, double\u2010blind, placebo\u2010controlled, phase 3 HERCULES study of caplacizumab in patients with acquired thrombotic thrombocytopenic purpura","volume":"130","author":"Scully","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1002\/rth2.12160_bb0080","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/jth.13571","article-title":"Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies","volume":"15","author":"Scully","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12160_bb0085","doi-asserted-by":"crossref","first-page":"E644","DOI":"10.1002\/ajh.24885","article-title":"Diagnosis of thrombotic thrombocytopenic purpura among patients with ADAMTS13 Activity 10%\u201020","volume":"92","author":"Ayanambakkam","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1002\/rth2.12160_bb0090","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1056\/NEJM199108083250605","article-title":"Improved survival in thrombotic thrombocytopenic purpura\u2010hemolytic uremic syndrome. Clinical experience in 108 patients","volume":"325","author":"Bell","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12160_bb0095","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1111\/trf.12917","article-title":"Plasma exchange complications in patients treated for thrombotic thrombocytopenia purpura\u2010hemolytic uremic syndrome: 2011 to 2014","volume":"54","author":"McClain","year":"2014","journal-title":"Transfusion"},{"key":"10.1002\/rth2.12160_bb0100","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/bloodadvances.2017009308","article-title":"Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune\u2010mediated thrombotic thrombocytopenic purpura","volume":"1","author":"Cataland","year":"2017","journal-title":"Blood Adv"},{"key":"10.1002\/rth2.12160_bb0105","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00277-009-0877-5","article-title":"High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study","volume":"89","author":"Balduini","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1002\/rth2.12160_bb0110","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/trf.14193","article-title":"Rituximab for thrombotic thrombocytopenic purpura: lessons from the STAR trial","volume":"57","author":"Uhl","year":"2017","journal-title":"Transfusion"},{"key":"10.1002\/rth2.12160_bb0115","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/j.1538-7836.2010.03818.x","article-title":"Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura","volume":"8","author":"McDonald","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12160_bb0120","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/CCM.0b013e31822e9d66","article-title":"Efficacy and safety of first\u2010line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center","volume":"40","author":"Froissart","year":"2012","journal-title":"Crit Care Med"},{"issue":"3","key":"10.1002\/rth2.12160_bb0125","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/jth.12114","article-title":"Rituximab for thrombotic thrombocytopenic purpura (TTP): benefit of early administration during acute episodes and use of prophylaxis to prevent relapse","volume":"11","author":"Westwood","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12160_bb0130","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/ajh.24559","article-title":"Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: results of a phase II, multicenter noncomparative study","volume":"91","author":"Benhamou","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1002\/rth2.12160_bb0135","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully","year":"2011","journal-title":"Blood"},{"issue":"24","key":"10.1002\/rth2.12160_bb0140","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1182\/blood-2016-03-703827","article-title":"Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura","volume":"127","author":"Page","year":"2016","journal-title":"Blood"},{"key":"10.1002\/rth2.12160_bb0145","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura","volume":"115","author":"Hovinga","year":"2010","journal-title":"Blood"},{"key":"10.1002\/rth2.12160_bb0150","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1046\/j.1537-2995.2000.40080896.x","article-title":"Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura\u2010hemolytic\u2010uremic syndrome","volume":"40","author":"Rizvi","year":"2000","journal-title":"Transfusion"},{"key":"10.1002\/rth2.12160_bb0155","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12160_bb0160","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3324\/haematol.2011.049676","article-title":"Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency\u2010associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience","volume":"97","author":"Benhamou","year":"2012","journal-title":"Haematologica"},{"key":"10.1002\/rth2.12160_bb0165","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1055\/s-0037-1614408","article-title":"Recovery and half\u2010life of von Willebrand factor\u2010cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura","volume":"81","author":"Furlan","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1002\/rth2.12160_bb0170","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2017-06-788026","article-title":"Recombinant ADAMTS\u201013: first\u2010in\u2010human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura","volume":"130","author":"Scully","year":"2017","journal-title":"Blood"},{"key":"10.1002\/rth2.12160_bb0175","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1182\/blood-2011-12-399501","article-title":"Gain\u2010of\u2010function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura","volume":"119","author":"Jian","year":"2012","journal-title":"Blood"},{"key":"10.1002\/rth2.12160_bb0180","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1182\/blood-2016-06-720086","article-title":"Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A","volume":"129","author":"Cannavo","year":"2017","journal-title":"Blood"},{"key":"10.1002\/rth2.12160_bb0185","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1182\/blood-2012-02-410431","article-title":"Improving on nature: redesigning ADAMTS13","volume":"119","author":"Kremer Hovinga","year":"2012","journal-title":"Blood"},{"key":"10.1002\/rth2.12160_bb0190","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/bjh.13993","article-title":"Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura","volume":"173","author":"Patriquin","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1002\/rth2.12160_bb0195","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.11739","article-title":"ADAMTS13 and anti\u2010ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission","volume":"93","author":"Peyvandi","year":"2008","journal-title":"Haematologica"},{"key":"10.1002\/rth2.12160_bb0200","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1365-2141.2008.07107.x","article-title":"Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse","volume":"141","author":"Jin","year":"2008","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1002\/rth2.12160_bb0205","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1182\/blood-2014-01-550244","article-title":"Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura: experience of the French Thrombotic Microangiopathies Reference Center","volume":"124","author":"Hie","year":"2014","journal-title":"Blood"},{"key":"10.1002\/rth2.12160_bb0210","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/bloodadvances.2017008268","article-title":"Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens","volume":"1","author":"Westwood","year":"2017","journal-title":"Blood Adv"},{"issue":"20","key":"10.1002\/rth2.12160_bb0215","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/blood-2018-04-840090","article-title":"Preemptive rituximab prevents long\u2010term relapses in immune\u2010mediated thrombotic thrombocytopenic purpura","volume":"132","author":"Jestin","year":"2018","journal-title":"Blood"},{"key":"10.1002\/rth2.12160_bb0220","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1182\/blood-2017-04-636431","article-title":"Pathophysiology of thrombotic thrombocytopenic purpura","volume":"130","author":"Sadler","year":"2017","journal-title":"Blood"},{"key":"10.1002\/rth2.12160_bb0225","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3899\/jrheum.150051","article-title":"Longterm safety of rituximab: final report of the Rheumatoid Arthritis Global Clinical Trial Program over 11\u00a0years","volume":"42","author":"van Vollenhoven","year":"2015","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1002\/rth2.12160_bb0230","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3324\/haematol.2016.151407","article-title":"Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers","volume":"103","author":"Hrdinova","year":"2018","journal-title":"Haematologica"},{"key":"10.1002\/rth2.12160_bb0235","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1172\/JCI65689","article-title":"B cell depletion in immune thrombocytopenia reveals splenic long\u2010lived plasma cells","volume":"123","author":"Mahevas","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1002\/rth2.12160_bb0240","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1182\/blood-2017-06-789578","article-title":"BAFF and CD4(+) T cells are major survival factors for long\u2010lived splenic plasma cells in a B\u2010cell\u2010depletion context","volume":"131","author":"Thai","year":"2018","journal-title":"Blood"},{"key":"10.1002\/rth2.12160_bb0245","first-page":"320","article-title":"Splenectomy in relapsing and plasma\u2010refractory acquired thrombotic thrombocytopenic purpura","volume":"89","author":"Kremer Hovinga","year":"2004","journal-title":"Haematologica"},{"key":"10.1002\/rth2.12160_bb0250","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2141.2005.05681.x","article-title":"Splenectomy for the treatment of thrombotic thrombocytopenic purpura","volume":"130","author":"Kappers\u2010Klunne","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1002\/rth2.12160_bb0255","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1182\/blood-2013-04-496752","article-title":"Multiple major morbidities and increased mortality during long\u2010term follow\u2010up after recovery from thrombotic thrombocytopenic purpura","volume":"122","author":"Deford","year":"2013","journal-title":"Blood"},{"key":"10.1002\/rth2.12160_bb0260","doi-asserted-by":"crossref","first-page":"e1598","DOI":"10.1097\/MD.0000000000001598","article-title":"Risk factors for autoimmune diseases development after thrombotic thrombocytopenic purpura","volume":"94","author":"Roriz","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1002\/rth2.12160_bb0265","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/ajh.24060","article-title":"Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura","volume":"90","author":"Han","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1002\/rth2.12160_bb0270","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood.V98.6.1765","article-title":"Specific von Willebrand factor\u2010cleaving protease in thrombotic microangiopathies: a study of 111 cases","volume":"98","author":"Veyradier","year":"2001","journal-title":"Blood"},{"key":"10.1002\/rth2.12160_bb0275","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/ejh.12706","article-title":"Twice\u2010daily therapeutical plasma exchange\u2010based salvage therapy in severe autoimmune thrombotic thrombocytopenic purpura: the French TMA Reference Center experience","volume":"97","author":"Soucemarianadin","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1002\/rth2.12160_bb0280","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2016-12-758656","article-title":"Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune\u2010mediated thrombotic thrombocytopenic purpura","volume":"130","author":"Alwan","year":"2017","journal-title":"Blood"},{"key":"10.1002\/rth2.12160_bb0285","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1111\/j.1537-2995.2010.02653.x","article-title":"The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange","volume":"50","author":"Bentley","year":"2010","journal-title":"Transfusion"},{"key":"10.1002\/rth2.12160_bb0290","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/bjh.13568","article-title":"A proposal: the need for thrombotic thrombocytopenic purpura Specialist Centres\u2014providing better outcomes","volume":"170","author":"Dutt","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1002\/rth2.12160_bb0295","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.revmed.2015.10.354","article-title":"Telemedicine in thrombotic microangiopathies: a way forward in rare diseases requiring emergency care","volume":"37","author":"Coppo","year":"2016","journal-title":"Rev Med Interne"},{"key":"10.1002\/rth2.12160_bb0300","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1537-2995.2004.00626.x","article-title":"Severe deficiency of VWF\u2010cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients","volume":"44","author":"Raife","year":"2004","journal-title":"Transfusion"},{"key":"10.1002\/rth2.12160_bb0305","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1600-0609.2009.01331.x","article-title":"Demographic and ADAMTS13 biomarker data as predictors of early recurrences of idiopathic thrombotic thrombocytopenic purpura","volume":"83","author":"Cataland","year":"2009","journal-title":"Eur J Haematol"},{"issue":"5","key":"10.1002\/rth2.12160_bb0310","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1365-2141.2010.08385.x","article-title":"Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura","volume":"151","author":"Lotta","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1002\/rth2.12160_bb0315","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2169\/internalmedicine.49.2706","article-title":"Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998\u20102008","volume":"49","author":"Fujimura","year":"2010","journal-title":"Intern Med"},{"key":"10.1002\/rth2.12160_bb0320","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1056\/NEJMc1213206","article-title":"ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura","volume":"368","author":"Shortt","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12160_bb0325","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1172\/JCI41062","article-title":"N\u2010acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice","volume":"121","author":"Chen","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1002\/rth2.12160_bb0330","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1182\/blood-2016-09-738856","article-title":"N\u2010acetylcysteine in preclinical mouse and baboon models of thrombotic thrombocytopenic purpura","volume":"129","author":"Tersteeg","year":"2017","journal-title":"Blood"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Frth2.12160","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922015072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922015072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/rth2.12160\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:16:52Z","timestamp":1762863412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037922015072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S2475037922015072"],"URL":"https:\/\/doi.org\/10.1002\/rth2.12160","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicine","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1002\/rth2.12160","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 The Authors. Research and Practice in Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}]}}